Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trialDouglas R. Adkins, Peter Oppelt, Jessica Ley et al.|The Lancet Oncology|2019Cited by 125
Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trialDouglas R. Adkins, Peter Oppelt, Jingxia Liu et al.|Oral Oncology|2021Cited by 31
Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trialPeter Oppelt, Douglas R. Adkins, Jessica Ley et al.|Oral Oncology|2021Cited by 21
nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trialPeter Oppelt, Douglas R. Adkins, Jessica Ley et al.|Medical Oncology|2021Cited by 18
Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).Douglas R. Adkins, Nabil F. Saba, Jessica Ley et al.|Journal of Clinical Oncology|2018Cited by 17